January 2020 - When do the patents on KEYTRUDA expire, and when will biosimilar KEYTRUDA enter the market?

Sponsor	Phase
Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Phase 2
OncoImmune, Inc.	Phase 1/Phase 2
The Methodist Hospital System	Phase 2

Sponsor

Phase

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase 2

OncoImmune, Inc.

Phase 1/Phase 2

The Methodist Hospital System

Phase 2

Petitioner	Date
Genome & Company	2018-10-02

Petitioner

Date

Genome & Company

2018-10-02

These patents were identified by searching patent claims

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Merck Sharp Dohme	KEYTRUDA	pembrolizumab	POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER	125514	001	2014-09-04	Start Trial	Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)	2035-06-26	RX		search
Merck Sharp Dohme	KEYTRUDA	pembrolizumab	POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER	125514	001	2014-09-04	Start Trial	Oncomatryx Biopharma, S.L. (Derio, ES)	2034-02-06	RX		search
Merck Sharp Dohme	KEYTRUDA	pembrolizumab	POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER	125514	001	2014-09-04	Start Trial	KANGPU BIOPHARMACEUTICALS, LTD. (Shanghai, CN)	2034-10-30	RX		search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

Country

Patent Number

Estimated Expiration

>Country

>Patent Number

>Estimated Expiration

Patents:	85
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for KEYTRUDA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for KEYTRUDA

KEYTRUDA Drug Profile